Detailed interpretation of the therapeutic effect and mechanism of Osimertinib/Tagrisso

Osimertinib/Tagrisso (Osimertinib) is a targeted therapy drug that is widely used in the treatment of non-small cell lung cancer (NSCLC), especially for patients carrying EGFR mutations. EGFR (epidermal growth factor receptor) mutation is a common driver mutation in non-small cell lung cancer. By targeting and inhibiting this mutation, osimertinib can significantly delay tumor progression and improve patients' quality of life.

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI). Compared with first- and second-generation TKIs, its biggest advantage is its ability to effectively inhibit the EGFR T790M mutation, which is usually the main cause of drug resistance in previous generations of TKIs. Therefore, osimertinib has become the first-line treatment for patients with EGFR T790M mutation-positive non-small cell lung cancer. Especially for those patients who are resistant to traditional targeted drugs such as gefitinib or erlotinib, osimertinib provides a better treatment option.

In addition to its outstanding performance in the treatment of T790M mutated non-small cell lung cancer patients, osimertinib also showed good efficacy in untreated patients with EGFR mutated non-small cell lung cancer. Clinical studies have shown that osimertinib can significantly improve progression-free survival (PFS) and overall survival (OS), and in many patients, tumor shrinkage is also very significant, further proving its important role in the treatment of non-small cell lung cancer.

In addition, the side effects of osimertinib are relatively mild, with common adverse reactions including rash, diarrhea, oral ulcers and minor respiratory problems. Compared with traditional chemotherapy drugs, the side effects of osimertinib are more controllable, and the patient's quality of life is guaranteed to a certain extent. However, in some cases, individual patients may experience more serious side effects, such as interstitial lung disease, which require close monitoring.

Reference materials:https://go.drugbank.com/drugs/DB09330